Drugs and Pills 1

Total Page：16

File Type：pdf, Size：1020Kb

AccuTOF TM with DART TM Direct Analysis of Drugs in Pills and Capsules with No Sample Preparation The AccuTOFtm equipped with Direct Analysis in Real prescription drugs, over-the-counter Time (DARTtm) is capable of analyzing drugs in pills and medicines, and illicit drugs that were capsules with no sample preparation. In most cases, the confiscated by a law-enforcement pill can simply be placed in front of the DART and the agency. active ingredients can be detected within seconds. This application note shows a wide variety of pills that have been analyzed by using DART. The examples include Acetaminophen [M+H]+ Examples of Pills and Medicines that Have Been Analyzed Directly by DART Oxycodone [M+H]+ OTC Medicines • Ibuprofen (anti-inflammatory) • Naproxen sodium (anti-inflammatory) • 150 200 250 300 350 Aspirin (anti-inflammatory) Mass • Acetaminophen (“Tylenol®” painkiller) • Sudafed® (pseudoephedrine decongestant) Endocet tablet (oxycodone: narcotic) • Melatonin (sleep aid) • Chlortrimeton (antihistamine) + [M+H] • Cough syrup (guaiafenesin and dextromethorphan) • Codeine with Tylenol® (painkiller) Prescription Drugs • Generic Wellbutrin® (Bupropion 100 200 300 400 500 m/z antidepressant) Lotensin Tablet (Benazepril: Antihypertensive) • Zantac® (ranitidine: histamine H 2 -receptor antagonist) Sealed capsule. • ® MDMA Lipitor (atorvastatin: treatment of [M+H]+ hypercholesterolemia) • Endocet® (oxycodone plus acetaminophen) • Levsin® sublingual tablet (Hyoscyamine anticholinergic) Dietary Supplements and Herbal Medicines 100 150 200 250 • Coenzyme Q10 with Vitamin E and Di- and “Ecstasy” (MDMA: illegal drug) Triglycerides • Magnolia Bark (Chinese herbal medicine) • [M+H]+ Conjugated Linoleic Acid (“CLA” weight- loss formulation) Confiscated Illicit Drugs • Dimethoxyamphetamine plus methamphetamine • Methylenedioxymethamphetamine 100 150 200 250 (“Ecstasy” or MDMA) m/z • OxyContin® Generic Wellbutrin (Bupropion antidepressant) All brand names are registered trademarks of their respective manufacturers. MS-0501I 11 Dearborn Road, Peabody, MA 01960 Tel: (978) 535-5900 • Fax: (978) 536-2205 [email protected] • www.jeol.com.

Copy Link

Recommended publications

WELLBUTRIN SR Safely and Effectively
HIGHLIGHTS OF PRESCRIBING INFORMATION psychosis, hallucinations, paranoia, delusions, homicidal ideation, These highlights do not include all the information needed to use aggression, hostility, agitation, anxiety, and panic, as well as suicidal WELLBUTRIN SR safely and effectively. See full prescribing ideation, suicide attempt, and completed suicide. Observe patients information for WELLBUTRIN SR. attempting to quit smoking with bupropion for the occurrence of such symptoms and instruct them to discontinue bupropion and contact a WELLBUTRIN SR (bupropion hydrochloride) sustained-release tablets, healthcare provider if they experience such adverse events. (5.2) for oral use • Initial U.S. Approval: 1985 Seizure risk: The risk is dose-related. Can minimize risk by gradually increasing the dose and limiting daily dose to 400 mg. Discontinue if WARNING: SUICIDAL THOUGHTS AND BEHAVIORS seizure occurs. (4, 5.3, 7.3) See full prescribing information for complete boxed warning. • Hypertension: WELLBUTRIN SR can increase blood pressure. Monitor blood pressure before initiating treatment and periodically during • Increased risk of suicidal thinking and behavior in children, treatment. (5.4) adolescents and young adults taking antidepressants. (5.1) • Activation of mania/hypomania: Screen patients for bipolar disorder and • Monitor for worsening and emergence of suicidal thoughts and monitor for these symptoms. (5.5) behaviors. (5.1) • Psychosis and other neuropsychiatric reactions: Instruct patients to contact a healthcare professional if such reactions occur. (5.6) --------------------------- INDICATIONS AND USAGE ---------------------------- • Angle-closure glaucoma: Angle-closure glaucoma has occurred in WELLBUTRIN SR is an aminoketone antidepressant, indicated for the patients with untreated anatomically narrow angles treated with treatment of major depressive disorder (MDD). (1) antidepressants.
[Show full text]
Concomitant Drugs Associated with Increased Mortality for MDMA Users Reported in a Drug Safety Surveillance Database Isaac V
www.nature.com/scientificreports OPEN Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database Isaac V. Cohen1, Tigran Makunts2,3, Ruben Abagyan2* & Kelan Thomas4 3,4-Methylenedioxymethamphetamine (MDMA) is currently being evaluated by the Food and Drug Administration (FDA) for the treatment of post-traumatic stress disorder (PTSD). If MDMA is FDA-approved it will be important to understand what medications may pose a risk of drug– drug interactions. The goal of this study was to evaluate the risks due to MDMA ingestion alone or in combination with other common medications and drugs of abuse using the FDA drug safety surveillance data. To date, nearly one thousand reports of MDMA use have been reported to the FDA. The majority of these reports include covariates such as co-ingested substances and demographic parameters. Univariate and multivariate logistic regression was employed to uncover the contributing factors to the reported risk of death among MDMA users. Several drug classes (MDMA metabolites or analogs, anesthetics, muscle relaxants, amphetamines and stimulants, benzodiazepines, ethanol, opioids), four antidepressants (bupropion, sertraline, venlafaxine and citalopram) and olanzapine demonstrated increased odds ratios for the reported risk of death. Future drug–drug interaction clinical trials should evaluate if any of the other drug–drug interactions described in our results actually pose a risk of morbidity or mortality in controlled medical settings. 3,4-Methylenedioxymethamphetamine (MDMA) is currently being evaluated by the Food and Drug Adminis- tration (FDA) for the treatment of posttraumatic stress disorder (PTSD). During the past two decades, “ecstasy” was illegally distributed and is purported to contain MDMA, but because the market is unregulated this “ecstasy” may actually contain adulterants or no MDMA at all1.
[Show full text]
Federal Register/Vol. 70, No. 42/Friday, March 4, 2005
Federal Register / Vol. 70, No. 42 / Friday, March 4, 2005 / Notices 10677 Drug Schedule Drug Schedule Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, Cathinone (1235) .......................... I Alpha-Methylfentanyl (9814) ........ I the above named company is granted Methcathinone (1237) .................. I Acetyl-alpha-methylfentanyl I registration as a bulk manufacturer of N-Ethylamphetamine (1475) ........ I (9815). the basic classes of controlled N,N-Dimethylamphetamine (1480) I Beta-hydroxyfentanyl (9830) ........ I substances listed. Aminorex (1585) ........................... I Beta-hydroxy-3-methylfentanyl I 4-7Methylaminorex (cis isomer) I (9831). Dated: Febuary 22, 2005. (1590). Alpha-Methylthiofentanyl (9832) ... I William J. Walker, Gamma hydroxybutyric acid I 3–Methylthiofentanyl (9833) ......... I Deputy Assistant Administrator, Office of Thiofentanyl (9835) ...................... I (2010). Diversion Control, Drug Enforcement Amphetamine (1100) .................... II Methaqualone (2565) ................... I Administration. Alpha-Ethyltryptamine (7249) ....... I Methamphetamine (1105) ............ II Lysergic acid diethylamide (7315) I Phenmetrazine (1631) .................. II [FR Doc. 05–4205 Filed 3–3–05; 8:45 am] Tetrahydrocannabinols (7370) ..... I Methylphenidate (1724) ................ II BILLING CODE 4410–09–P Mescaline (7381) .......................... I Ambobarbital (2125) ..................... II 3,4,5-Trimethoxyamphetamine I Pentobarbital (2270) ..................... II (7390).
[Show full text]
SENATE BILL No. 259 No
SENATE BILL No. 259 SENATE BILL No. 259 March 10, 2011, Introduced by Senators JONES, CASPERSON and SCHUITMAKER and referred to the Committee on Judiciary. A bill to amend 1978 PA 368, entitled "Public health code," by amending section 7212 (MCL 333.7212), as amended by 2010 PA 171. THE PEOPLE OF THE STATE OF MICHIGAN ENACT: 1 Sec. 7212. (1) The following controlled substances are 2 included in schedule 1: 3 (a) Any of the following opiates, including their isomers, 4 esters, the ethers, salts, and salts of isomers, esters, and 5 ethers, unless specifically excepted, when the existence of these 6 isomers, esters, ethers, and salts is possible within the 7 specific chemical designation: SENATE BILL No. 259 00981'11 TLG 2 1 Acetylmethadol Difenoxin Noracymethadol 2 Allylprodine Dimenoxadol Norlevorphanol 3 Alpha-acetylmethadol Dimepheptanol Normethadone 4 Alphameprodine Dimethylthiambutene Norpipanone 5 Alphamethadol Dioxaphetyl butyrate Phenadoxone 6 Benzethidine Dipipanone Phenampromide 7 Betacetylmethadol Ethylmethylthiambutene Phenomorphan 8 Betameprodine Etonitazene Phenoperidine 9 Betamethadol Etoxeridine Piritramide 10 Betaprodine Furethidine Proheptazine 11 Clonitazene Hydroxypethidine Properidine 12 Dextromoramide Ketobemidone Propiram 13 Diampromide Levomoramide Racemoramide 14 Diethylthiambutene Levophenacylmorphan Trimeperidine 15 Morpheridine 16 (b) Any of the following opium derivatives, their salts, 17 isomers, and salts of isomers, unless specifically excepted, when 18 the existence of these salts, isomers, and salts of
[Show full text]
3,4-Methylenedioxymethcathinone (Methylone) [“Bath Salt,” Bk-MDMA, MDMC, MDMCAT, “Explosion,” “Ease,” “Molly”] December 2019
Drug Enforcement Administration Diversion Control Division Drug & Chemical Evaluation Section 3,4-Methylenedioxymethcathinone (Methylone) [“Bath salt,” bk-MDMA, MDMC, MDMCAT, “Explosion,” “Ease,” “Molly”] December 2019 Introduction: discriminate DOM from saline. 3,4-Methylenedioxymethcathinone (methylone) is a Because of the structural and pharmacological similarities designer drug of the phenethylamine class. Methylone is a between methylone and MDMA, the psychoactive effects, adverse synthetic cathinone with substantial chemical, structural, and health risks, and signs of intoxication resulting from methylone pharmacological similarities to 3,4-methylenedioxymeth- abuse are likely to be similar to those of MDMA. Several chat amphetamine (MDMA, ecstasy). Animal studies indicate that rooms discussed pleasant and positive effects of methylone when methylone has MDMA-like and (+)-amphetamine-like used for recreational purpose. behavioral effects. When combined with mephedrone, a controlled schedule I substance, the combination is called User Population: “bubbles.” Other names are given in the above title. Methylone, like other synthetic cathinones, is a recreational drug that emerged on the United States’ illicit drug market in 2009. It is perceived as being a ‘legal’ alternative to drugs of Licit Uses: Methylone is not approved for medical use in the United abuse like MDMA, methamphetamine, and cocaine. Evidence States. indicates that youths and young adults are the primary users of synthetic cathinone substances which include methylone. However, older adults also have been identified as users of these Chemistry: substances. O H O N CH3 Illicit Distribution: CH O 3 Law enforcement has encountered methylone in the United States as well as in several countries including the Netherlands, Methylone United Kingdom, Japan, and Sweden.
[Show full text]
(19) United States (12) Patent Application Publication (10) Pub
US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
[Show full text]
Precursors and Chemicals Frequently Used in the Illicit Manufacture Of
40 INCB REPORT ON PRECURSORS 2019 • 2,5-Dimethoxybenzaldehyde, a precursor for 2,5-dimethoxyamphetamine (DMA), brolamfetamine IV. Article 13 of the (DOB) and the 2C-series of controlled psychotropic substances, as well as for new psychoactive substances, 1988 Convention as reported by the Netherlands (5 kg) and Belgium (1 kg). a complementary tool in addressing • 4-Methoxy-P-2-P, a precursor of para-methoxy- alpha-methylphenethylamine (PMA) and para- illicit drug methoxymethylamphetamine (PMMA), reported by Spain (52 kg). manufacture 226. Through PICS, incidents involving 2-bromo- 4’-chloropropiophenone, a precursor of various 4-chloro- 229. The clandestine manufacture of narcotic drugs and substituted cathinone derivatives, such as 4-CMC psychotropic substances, new psychoactive substances and (clephedrone), were communicated. Luxembourg seized precursors is not possible without the input of chemicals, 500 kg of the substance in August 2018. The consignment materials and equipment. While the control of chemicals was confiscated because both the supplier and the con- has long been a focus of the authorities worldwide, pursu- signee were already known in connection with shipments ant to the provisions in article 12 of the 1988 Convention, of other precursors of new psychoactive substances. It much less attention has been given to equipment and originated in India, transited Qatar, Luxembourg and materials and article 13 of that Convention, which pro- Germany and was destined for a consignee in Poland. A vides a basis for international action and cooperation in consignment of 300 kg of the substance was confiscated by such control efforts (see box 5). customs authorities in Germany in December 2018.
[Show full text]
Pharmacology and Toxicology of Amphetamine and Related Designer Drugs
Pharmacology and Toxicology of Amphetamine and Related Designer Drugs U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol Drug Abuse and Mental Health Administration Pharmacology and Toxicology of Amphetamine and Related Designer Drugs Editors: Khursheed Asghar, Ph.D. Division of Preclinical Research National Institute on Drug Abuse Errol De Souza, Ph.D. Addiction Research Center National Institute on Drug Abuse NIDA Research Monograph 94 1989 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 Pharmacology and Toxicology of Amphetamine and Related Designer Drugs ACKNOWLEDGMENT This monograph is based upon papers and discussion from a technical review on pharmacology and toxicology of amphetamine and related designer drugs that took place on August 2 through 4, 1988, in Bethesda, MD. The review meeting was sponsored by the Biomedical Branch, Division of Preclinical Research, and the Addiction Research Center, National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other matieral in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors.
[Show full text]
Drugs and Medical Devices Group
The Deputy Administrator of the Drug Enforcement Administration (DEA) issued a notice of intent temporarily placing the substance 2,5-dimethoxy-4-(n)- propylthiophenethylamine (2C-T-7), including its optical isomers, salts, and salts of isomers into Schedule I of the Federal Controlled Substances Act (CSA). 2C-T-7 is structurally related to the Schedule I substance 4-bromo-2,5-dimethoxyphenethylamine (2C-B), and it has those structural features of phenethylamines which are necessary for stimulant and/or hallucinogenic activity. There is no approved therapeutic use of 2C-T-7 in the United States, and the safety of this substance has never been demonstrated. This action was based on the following: (1) 2,5-dimethoxy-4-(n)-propylthiophenethylamine is structurally and pharmacologically related to other Schedule I hallucinogens; (2) 2,5-dimethoxy-4-(n)-propylthiophenethylamine has no accepted therapeutic use in the United States and is not safe for use under medical supervision; and, (3) 2,5-dimethoxy-4-(n)-propylthiophenethylamine has a high potential for abuse, similar to other Schedule I phenethylamines. Pursuant to Section 481.034(g), as amended by the 75th legislature, of the Texas Controlled Substances Act, Chapter 481, Health and Safety Code, at least thirty-one days have expired since notice of the above referenced action was published in the Federal Register, and in my capacity as Commissioner of the Texas Department of Health, I do hereby order that the substance 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7), its optical isomers, salts, and salts of isomers be added to Schedule I of the Texas Controlled Substances Act.
[Show full text]
MEDICATION GUIDE WELLBUTRIN® (WELL Byu-Trin) (Bupropion Hydrochloride) Tablets
NDA 018644/S-041 NDA 020358/S-048 Page 6 MEDICATION GUIDE WELLBUTRIN® (WELL byu-trin) (bupropion hydrochloride) Tablets Read this Medication Guide carefully before you start using WELLBUTRIN and each time you get a refill. There may be new information. This information does not take the place of talking with your doctor about your medical condition or your treatment. If you have any questions about WELLBUTRIN, ask your doctor or pharmacist. IMPORTANT: Be sure to read the three sections of this Medication Guide. The first section is about the risk of suicidal thoughts and actions with antidepressant medicines; the second section is about the risk of changes in thinking and behavior, depression and suicidal thoughts or actions with medicines used to quit smoking; and the third section is entitled “What Other Important Information Should I Know About WELLBUTRIN?” Antidepressant Medicines, Depression and Other Serious Mental Illnesses, and Suicidal Thoughts or Actions This section of the Medication Guide is only about the risk of suicidal thoughts and actions with antidepressant medicines. Talk to your, or your family member’s, healthcare provider about: • all risks and benefits of treatment with antidepressant medicines • all treatment choices for depression or other serious mental illness What is the most important information I should know about antidepressant medicines, depression and other serious mental illnesses, and suicidal thoughts or actions? 1. Antidepressant medicines may increase suicidal thoughts or actions in some children, teenagers, and young adults within the first few months of treatment. 2. Depression and other serious mental illnesses are the most important causes of suicidal thoughts and actions.
[Show full text]
Federal Register/Vol. 76, No. 228/Monday, November
Federal Register / Vol. 76, No. 228 / Monday, November 28, 2011 / Notices 72975 Dated: November 18, 2011. Drug Schedule (ODL), 8701 Morrissette Drive, Joseph T. Rannazzisi, Springfield, Virginia 22152; and must be Deputy Assistant Administrator, Office of 4-Anilino-N-phenethyl-4-piperidine II filed no later than January 27, 2012. (8333). Diversion Control, Drug Enforcement Dated: November 18, 2011. Administration. Codeine (9050) ............................. II Oxycodone (9143) ........................ II Joseph T. Rannazzisi, [FR Doc. 2011–30547 Filed 11–25–11; 8:45 am] Hydromorphone (9150) ................ II Deputy Assistant Administrator, Office of BILLING CODE 4410–09–P Hydrocodone (9193) ..................... II Diversion Control, Drug Enforcement Levorphanol (9220) ...................... II Administration. Methadone (9250) ........................ II [FR Doc. 2011–30544 Filed 11–25–11; 8:45 am] DEPARTMENT OF JUSTICE Methadone intermediate (9254) ... II BILLING CODE 4410–09–P Morphine (9300) ........................... II Drug Enforcement Administration Thebaine (9333) ........................... II Oxymorphone (9652) ................... II Manufacturer of Controlled DEPARTMENT OF JUSTICE Substances Notice of Application The company plans to manufacture Drug Enforcement Administration Pursuant to § 1301.33(a), Title 21 of the listed controlled substances as bulk the Code of Federal Regulations (CFR), controlled substances intermediates for Manufacturer of Controlled this is notice that on March 30, 2010, distribution to its customers.
[Show full text]
Antidepressant & Psychedelic Drug Interaction Chart
Copyright Psychedelic School 8/2020 Antidepressant & Psychedelic Drug Interaction Chart This chart is not intended to be used to make medical decisions and is for informational purposes only. It was constructed using data whenever possible, although extrapolation from known information was also used to inform risk. Any decision to start, stop, or taper medication and/or use psychedelic drugs should be made in conjunction with your healthcare provider(s). It is recommended to not perform any illicit activity. This chart the intellectual property of psychedelic school and is for personal use only. Please do not copy or distribute this chart. Antidepressant Phenethylamines Tryptamines MAOI-containing Ketamine Ibogaine -MDMA, mescaline -Psilocybin, LSD -Ayahuasca, Syrian Rue SSRIs Taper & discontinue at least 2 Consider taper & Taper & discontinue at least 2 Has been studied and Taper & discontinue at · Paroxetine (Paxil) weeks prior (all except discontinuation at least 2 weeks weeks prior (all except found effective both with least 2 weeks prior (all · Sertraline (Zoloft) fluoxetine) or 6 weeks prior prior (all except fluoxetine) or 6 fluoxetine) or 6 weeks prior and without concurrent except fluoxetine) or 6 · Citalopram (Celexa) (fluoxetine only) due to loss of weeks prior (fluoxetine only) (fluoxetine only) due to use of antidepressants weeks prior (fluoxetine · Escitalopram (Lexapro) psychedelic effect due to potential loss of potential risk of serotonin only) due to risk of · Fluxoetine (Prozac) psychedelic effect syndrome additive QTc interval · Fluvoxamine (Luvox) MDMA is unable to cause Recommended prolongation, release of serotonin when the Chronic antidepressant use may Life threatening toxicities can to be used in conjunction arrhythmias, or SPARI serotonin reuptake pump is result in down-regulation of occur with these with oral antidepressants cardiotoxicity · Vibryyd (Vilazodone) blocked.
[Show full text]